Home Newsfeeds Oramed Pharmaceuticals Q3 EPS $(0.18) Down From $(0.17) YoY

Oramed Pharmaceuticals Q3 EPS $(0.18) Down From $(0.17) YoY

Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly losses of $(0.18) per share. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.

byBenzinga Newsdesk

November 10, 2022

1 minute read

Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly losses of $(0.18) per share. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year.

Earnings

Mondelez International’s Return On Capital Employed Overview

By Benzinga Insights

May 1, 10:48 AM

According to Benzinga Pro, during Q1, Mondelez International (NASDAQ:MDLZ) earned $2.09 billion, a 257.71% increase from the preceding…

MDLZ

M&A
News

Synchronoss Technologies Confirms Receipt Of Non-Binding Proposal From B. Riley Financial To Acquire All Outstanding Shares Of The Company’s Common Stock For A Price Of $1.15 Per Share, Payable In Cash

By Happy Mohamed

March 13, 8:51 AM

Synchronoss Technologies Inc. ("Synchronoss" or the "Company") (NASDAQ:SNCR), a global leader and innovator in cloud, messaging, and digital products and platforms, today confirmed

SNCR